Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 20205570)

1.

Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.

Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, Clements JE.

J Infect Dis. 2010 Apr 15;201(8):1132-40. doi: 10.1086/651277.

2.

Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo.

Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB, Quinn TC, Siliciano RF.

J Virol. 2003 Jul;77(13):7383-92.

3.

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.

Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, Khoury G, Pereira C, Purcell D, Cameron PU, Lewin SR.

Retrovirology. 2011 Oct 12;8:80. doi: 10.1186/1742-4690-8-80.

4.

Can HIV infection be eradicated through use of potent antiviral agents?

Josefsson L, Dahl V, Palmer S.

Curr Opin Infect Dis. 2010 Dec;23(6):628-32. doi: 10.1097/QCO.0b013e32833ff1d0. Review.

PMID:
20847693
5.

Neuroprotective and anti-human immunodeficiency virus activity of minocycline.

Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S.

JAMA. 2005 Apr 27;293(16):2003-11.

PMID:
15855434
6.

Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.

Daniel V, Süsal C, Melk A, Weimer R, Kröpelin M, Zimmermann R, Huth-Kühne A, Uhle C, Opelz G.

Immunol Lett. 1999 Aug 3;69(2):283-9.

PMID:
10482364
7.

Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.

North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA.

J Virol. 2010 Mar;84(6):2913-22. doi: 10.1128/JVI.02356-09. Epub 2009 Dec 23.

8.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.

AIDS. 2012 Sep 24;26(15):1885-94.

PMID:
22992577
9.

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73.

10.

Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.

Mohey R, Jørgensen LB, Møller BK, Black FT, Kjems J, Obel N.

J Clin Virol. 2005 Dec;34(4):257-67. Epub 2005 Apr 18.

PMID:
16286049
11.

Glucocorticoids rescue CD4+ T lymphocytes from activation-induced apoptosis triggered by HIV-1: implications for pathogenesis and therapy.

Lu W, Salerno-Goncalves R, Yuan J, Sylvie D, Han DS, Andrieu JM.

AIDS. 1995 Jan;9(1):35-42.

PMID:
7893439
12.

Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.

Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.

J Immunol. 2005 Aug 1;175(3):2010-7.

13.

[Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].

Marcello A, Giacca M.

Pathologica. 2000 Aug;92(4):291-3. Italian. No abstract available.

PMID:
11029891
14.

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF.

Science. 1997 Nov 14;278(5341):1295-300.

15.

T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG.

J Infect Dis. 2003 May 15;187(10):1534-43. Epub 2003 Apr 23.

16.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM.

Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.

17.

Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals.

Fondere JM, Petitjean G, Huguet MF, Salhi SL, Baillat V, Macura-Biegun A, Becquart P, Reynes J, Vendrell JP.

J Virol. 2004 Oct;78(19):10536-42. Erratum in: J Virol. 2004 Nov;78(22):12722. Macura-Biegum, Anna [corrected to Macura-Biegun, Anna].

18.

Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells.

Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF.

PLoS Pathog. 2006 Jul;2(7):e68.

19.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk